(RTTNews) – Moderna, Inc. (MRNA) announced Tuesday that its next-generation COVID-19 vaccine design, mRNA-1283, met the number one endpoints of the Phase 3 NextCOVE clinical trial.
The trial showed a positive immune reaction against SARS-CoV-2 to Moderna’s legal COVID-19 vaccine, mRNA-1273. 222.
The NEXTCove involved approximately 11,400 participants over the age of 12 in the United States, the United Kingdom, and Canada.
The maximum side effects reported were pain at the injection site, headache, fatigue, myalgia, and chills.
Moderna said it will share a detailed study of the Phase 3 trial data for mRNA-1283 at the Vaccine Day event on March 27 and at upcoming clinical conferences.